Sep 12, 2022 / 08:00PM GMT
Ed Arce - H.C. Wainwright & Co. - Analyst
Hello, and welcome to the H.C. Wainwright 24th Annual Global Investment Conference. My name is Ed Arce, and I'm one of the senior biotech analysts here at HCW. And next up, I'm very pleased to have with us the President and CEO of 89bio, Rohan Palekar. Rohan, great to see.
Rohan Palekar - 89bio, Inc. - CEO
Great seeing you, Ed. Thanks for having us at the meeting.
Questions and Answers:
Ed Arce - H.C. Wainwright & Co. - AnalystAbsolutely. Glad you're here. So let's start by just having you provide a quick overview of the company, your programs, pipeline, and major upcoming milestones.
Rohan Palekar - 89bio, Inc. - CEO
Sure. So 89bio is a clinical-stage company focused on cardiometabolic and liver disorders. Our lead program, which we call pegozafermin, is an FGF21 analog, which has been modified to maximize its efficacy and ensure a long-dosing interval.
Now, we think FGF21 and pegozafermin has the potential
Trustpilot
